nach oben

Erschienen in:

09.10.2019 | original article

Clinicopathological importance of colorectal medullary carcinoma

verfasst von: Serkan Zenger, MD, Bulent Gurbuz, MD, Ugur Can, MD, Cagri Bilgic, MD, Erman Sobutay, MD, Serpil Postgil Yilmaz, MD, Prof. Emre Balik, MD, Prof. Tunc Yalti, MD, Prof. Yersu Kapran, MD, Prof. Dursun Bugra, MD

Erschienen in: European Surgery | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Summary

Purpose

Medullary carcinoma (MC) is a rare tumor with a solid growth pattern without glandular differentiation and constitutes less than 1% of colorectal cancers. Lymph node positivity and distant organ metastasis were reported to be lower than in other poorly differentiated adenocarcinomas. Therefore, the diagnosis of MC is pathologically important in terms of follow-up and treatment. We aimed to investigate the characteristics of medullary cancer in our case series.

Methods

427 patients with colorectal cancer (CRC) who underwent surgery between January 2011 and December 2017 were evaluated retrospectively in 2 groups as MC (n = 13) and non-MC (n = 414) in terms of demographic characteristics, pathological data, and oncological outcomes.

Results

76.9% (n = 10) of the MC group were female while 36% (n = 149) of the non-MC group were female (p = 0.003). The tumors were located in the right colon in 84.6% (n = 11) of the MC patients and in 26.6% (n = 110) of the non-MC patients (p < 0.001). The rate of laparoscopy was 83.8% for all CRC patients, and 53.8% for the MC group (p = 0.01). T4 cases (69.2%) and tumor volume (131 ± 87 cm³) in the MC group were significantly higher than in the non-MC group (p < 0.05). The rate of high microsatellite instability (MSI) was 85%. 5‑year overall survival was 75% for the patients with MC and 82% for non-MC (p = 0.13).

Conclusion

MC is commonly localized in the right colon, has a large tumor size, and is mostly diagnosed in the T4 stage. As MC most likely have defects in DNA MMR, correct pathological diagnosis is important for postoperative treatment and the prognosis of the patients.

Vorheriger Artikel Thyroidectomy using superficial cervical block: a report of 147 cases over 8 years

Nächster Artikel Psycho-oncological distress in patients with peritoneal surface malignancies treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.PubMed

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48.PubMedCentral

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.PubMed

Hamilton SR, Bosman FT, Boffetta P. WHO classification of tumours of the digestive system. In: Hamilton SR, Aaltonen LA, editors. Carcinoma of the colon and rectum. Lyon: IARC Press; 2010. pp. 134–46.

Thirunavukarasu P, Sathaiah M, Singla S, Sukumar S, Karunamurthy A, Pragatheeshwar KD, et al. Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol. 2010;37(4):901–7.PubMed

Winn B, Tavares R, Fanion J, Noble L, Gao J, Sabo E, et al. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation. Hum Pathol. 2009;40(3):398–404.PubMed

Knox RD, Luey N, Sioson L, Kedziora A, Clarkson A, Watson N, et al. Medullary colorectal carcinoma revisited: a clinical and pathological study of 102 cases. Ann Surg Oncol. 2015;22(9):2988–96.PubMed

Kirchner T, Reu S. Development of molecular-pathologic entities of colorectal cancer. Pathologe. 2008;29(Suppl 2):264–9.PubMed

Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338(21):1481–7.PubMed

10.

Gafa R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer. 2000;89(10):2025–37.PubMed

11.

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst. 2017; https://doi.org/10.1093/jnci/djx030.CrossRefPubMedPubMedCentral

12.

Gibbs NM. Undifferentiated carcinoma of the large intestine. Histopathology. 1977;1(1):77–84.PubMed

13.

Jessurun J, Romero-Guadarrama M, Manivel JC. Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases. Hum Pathol. 1999;30(7):843–8.PubMed

14.

Ruschoff J, Dietmaier W, Luttges J, Seitz G, Bocker T, Zirngibl H, et al. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150(5):1815–25.PubMedPubMedCentral

15.

Arai T, Esaki Y, Sawabe M, Honma N, Nakamura K, Takubo K. Hypermethylation of the hMLH1 promoter with absent hMLH1 expression in medullary-type poorly differentiated colorectal adenocarcinoma in the elderly. Mod Pathol. 2004;17(2):172–9.PubMed

16.

Fiehn AM, Grauslund M, Glenthoj A, Melchior LC, Vainer B, Willemoe GL. Medullary carcinoma of the colon: can the undifferentiated be differentiated? Virchows Arch. 2015;466(1):13–20.PubMed

17.

Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159(6):2239–48.PubMedPubMedCentral

18.

Lanza G, Gafa R, Matteuzzi M, Santini A. Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival. J Clin Oncol. 1999;17(8):2429–38.PubMed

19.

Friedman K, Brodsky AS, Lu S, Wood S, Gill AJ, Lombardo K, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol. 2016;29(5):528–41.PubMed

20.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.PubMedPubMedCentral

21.

Ghanipour A, Jirstrom K, Ponten F, Glimelius B, Pahlman L, Birgisson H. The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2949–56.PubMed

22.

Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–57.PubMed

23.

Carethers JM, Jung BH. Genetics and genetic biomarkers in Sporadic Colorectal Cancer. Gastroenterology. 2015;149(5):1177–1190.e3.PubMed

24.

Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer. 2008;7(1):41–52.PubMed

25.

Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158(2):527–35.PubMedPubMedCentral

26.

Ashktorab H, Ahuja S, Kannan L, Llor X, Ellis NA, Xicola RM, et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget. 2016;7(23):34546–57.PubMedPubMedCentral

27.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.PubMed

28.

Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147(6):1308–1316.e1.PubMed

29.

Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014;146(3):643–646.e8.PubMed

30.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol. 2009;27(11):1814–21.PubMedPubMedCentral

31.

Zaanan A, Flejou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res. 2011;17(23):7470–8.PubMed

32.

Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5‑fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126(2):394–401.PubMed

33.

Jo WS, Carethers JM. Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark. 2006;2(1–2):51–60.PubMedPubMedCentral

34.

Doganavsargil B, Yıldırım FU, Sezak M, Yaman B. Histopathological approach to colorectal medullary carcinomas and their clinicopathological importance. Turkish J Acad Gastroenterol. 2014;13(2):51–6.

35.

Lee LH, Yantiss RK, Sadot E, Ren B, Calvacanti MS, Hechtman JF, et al. Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Hum Pathol. 2017;62:74–82.PubMed

36.

Pyo JS, Sohn JH, Kang G. Medullary carcinoma in the colorectum: a systematic review and meta-analysis. Hum Pathol. 2016;53:91–6.PubMed

37.

Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE. Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol. 2005;123(1):56–65.PubMed

38.

Gündoğan E, Gündoğan GA, Özdemir G, Kement M. Rectum located medullary cancer: case report. Kocaeli Med J. 2017;6(2):72–4.

39.

Rosty C, Williamson EJ, Clendenning M, Walters RJ, Win AK, Jenkins MA, et al. Should the grading of colorectal adenocarcinoma include microsatellite instability status? Hum Pathol. 2014;45(10):2077–84.PubMed

40.

Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, et al. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS ONE. 2014;9(6):e100461.PubMedPubMedCentral

41.

Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, et al. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014;19(5):492–7.PubMedPubMedCentral

42.

Kazama Y, Watanabe T, Kanazawa T, Tanaka J, Tanaka T, Nagawa H. Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological features. J Clin Pathol. 2007;60(6):701–4.PubMedPubMedCentral

43.

Xiao H, Yoon YS, Hong SM, Roh SA, Cho DH, Yu CS, et al. Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival. Am J Clin Pathol. 2013;140(3):341–7.PubMed

44.

Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014;25(5):1032–8.PubMedPubMedCentral

45.

Nordholm-Carstensen A, Krarup PM, Morton D, Harling H, Danish Colorectal Cancer Group. Mismatch repair status and synchronous metastases in colorectal cancer: a nationwide cohort study. Int J Cancer. 2015;137(9):2139–48.PubMed

Titel: Clinicopathological importance of colorectal medullary carcinoma
verfasst von: Serkan Zenger, MD
Bulent Gurbuz, MD
Ugur Can, MD
Cagri Bilgic, MD
Erman Sobutay, MD
Serpil Postgil Yilmaz, MD
Prof. Emre Balik, MD
Prof. Tunc Yalti, MD
Prof. Yersu Kapran, MD
Prof. Dursun Bugra, MD
Publikationsdatum: 09.10.2019
Verlag: Springer Vienna
Erschienen in: European Surgery / Ausgabe 6/2019
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI: https://doi.org/10.1007/s10353-019-00613-3

Springer Medizin Österreich

Summary

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Giant hiatus hernia: closure of the difficult hiatus

Psycho-oncological distress in patients with peritoneal surface malignancies treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

New evidence defining the pathology and pathogenesis of lower esophageal sphincter damage

Long-term oncological outcome in thymic malignancies: videothoracoscopic versus open thymectomy

The gastric cardia: what it reveals about our society

Quantification of the effects of coffee on postoperative ileus after laparoscopic ventral rectopexy: a randomized controlled trial